Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

C4542

Sigma-Aldrich

Cyclobenzaprine hydrochloride

Sinônimo(s):

5-(3-Dimethylaminopropylidene)dibenzo[a,e]cycloheptatriene hydrochloride

Faça loginpara ver os preços organizacionais e de contrato


About This Item

Fórmula empírica (Notação de Hill):
C20H21N · HCl
Número CAS:
Peso molecular:
311.85
Número CE:
Número MDL:
Código UNSPSC:
12352200
ID de substância PubChem:
NACRES:
NA.77
Preço e disponibilidade não estão disponíveis no momento.

Formulário

powder

Nível de qualidade

originador

Johnson & Johnson

cadeia de caracteres SMILES

Cl.CN(C)CC\C=C1\c2ccccc2C=Cc3ccccc13

InChI

1S/C20H21N.ClH/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20;/h3-6,8-14H,7,15H2,1-2H3;1H

chave InChI

VXEAYBOGHINOKW-UHFFFAOYSA-N

Informações sobre genes

Procurando produtos similares? Visita Guia de comparação de produtos

Descrição geral

Cyclobenzaprine is a tricyclic agent, which has anti-depressant and anti-cholinergic properties.[1] It lowers the tonic somatic motor activity of motor neuron systems. Cyclobenzaprine prevents the uptake of noradrenaline. It is used to treat neck, back and myofascial pain.[2] Cyclobenzaprine functions as a nerve impulse inhibitor.[3]

Aplicação

Cyclobenzaprine hydrochloride has been used to study its effect on the muscles of dystrophin-deficient mdx5Cv mice.[4]
Cyclobenzaprine hydrochloride has been used to study its effects on the muscles of dystrophin-deficient mdx5Cv mice.[4]

Ações bioquímicas/fisiológicas

Cyclobenzaprine hydrochloride is a type of tricyclic skeletal drug,[5] which is commonly used as a muscle relaxant.[6][5] It is very effective in treating intractable pain of cervical and lumbar origin caused by skeletal muscle spasm.[5] cyclobenzaprine hydrochloride inhibit tonic α-mononeuronal excitation mediated by descending serotonergic systems by interacting with serotonin receptors at the spinal cord level.[7]
Skeletal muscle relaxant; 5-HT2 serotonin receptor antagonist.
Skeletal muscle relaxant; reduces muscle spasm by depression of brainstem neurons; 5-HT2 serotonin receptor antagonist.

Características e benefícios

This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictogramas

Skull and crossbones

Palavra indicadora

Danger

Frases de perigo

Classificações de perigo

Acute Tox. 3 Oral - Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation

Código de classe de armazenamento

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Equipamento de proteção individual

dust mask type N95 (US), Eyeshields, Faceshields, Gloves


Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

Não está vendo a versão correta?

Se precisar de uma versão específica, você pode procurar um certificado específico pelo número do lote ou da remessa.

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

H Kobayashi et al.
European journal of pharmacology, 311(1), 29-35 (1996-09-05)
The centrally acting muscle relaxant cyclobenzaprine was thought to be an alpha 2-adrenoceptor agonist that reduced muscle tone by decreasing the activity of descending noradrenergic neurons. In the present study, we examined the effects of cyclobenzaprine on descending neurons by
A validated inherent stability indicating HPTLC method for estimation of cyclobenzaprine hydrochloride in tablets and use of MS-QTOF in characterization of its alkaline stress degradation product
Harde MT, et al.
Bulletin of Faculty of Pharmacy, Cairo University , 54(2), 145-156 (2016)
Psychiatric Side Effects of Prescription and Over-the-counter Medications: Recognition and Management (1998)
Efficacy of a low-dose regimen of cyclobenzaprine hydrochloride in acute skeletal muscle spasm: results of two placebo-controlled trials
Borenstein DG and Korn S
Clinical Therapeutics, 25(4), 1056-1073 (2003)
Determination of degradation products of Cyclobenzaprine hydrochloride, Lidocaine and Piroxicam in a semi-topical formulation: MS-MS confirmation of unknown impurities
Cioroiu BI, et al.
Journal of Chromatographic Science, 54(6), 902-911 (2016)

Questions

Reviews

No rating value

Active Filters

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica